Tirzepatide products available in the UK: what you're actually getting

Picture the moment your pen arrives: here's what you're holding

When a Mounjaro KwikPen reaches you (tracked by DPD, in plain unmarked packaging) it looks a lot like an EpiPen. Inside, a pre-filled cartridge holds enough tirzepatide solution for four weekly injections at a single dose strength. You dial, press and hold; there's no needle to assemble and no vial to draw from. Each pen covers roughly one month of treatment, which is why the medicine is often discussed in monthly terms even though dosing is weekly.

The pen you receive corresponds to the strength your prescriber has selected for that point in your titration. Treatment begins at 2.5 mg, a dose whose job is to help your body adjust, not to produce the bulk of the therapeutic effect. From there, the prescriber typically steps the dose up every four weeks, assessing how you're tolerating each level before moving to the next. The six UK strengths (2.5, 5, 7.5, 10, 12.5 and 15 mg) give prescribers room to find the highest dose you tolerate well. You can read a full clinical overview of the medicine on the tirzepatide information page.

Storage matters: the pen should be kept refrigerated between 2–8°C until you're ready to use it. The exact window for keeping it at room temperature before use is detailed in the Patient Information Leaflet supplied with each pen, and that's the figure to follow, not any general guidance you read online.

Why tirzepatide sits apart from other weight-loss injections

The thing that separates tirzepatide from other injectable weight-loss medicines is its mechanism. Most GLP-1 medicines (including semaglutide (Wegovy)) act on a single receptor pathway. Tirzepatide acts on two: the GLP-1 receptor and the GIP receptor. Both are involved in appetite regulation, insulin response and the rate at which food moves through the stomach. Activating both pathways simultaneously appears to produce a larger and more sustained reduction in appetite than single-agonist approaches in most people.

The clinical evidence reflects this. The SURMOUNT-1 trial involved 2,539 adults with obesity and reported average weight reductions of roughly 20–21% at the 15 mg dose over 72 weeks, as published in the New England Journal of Medicine. A later head-to-head trial, SURMOUNT-5, showed tirzepatide produced greater average weight loss than semaglutide 2.4 mg over 72 weeks. NICE reviewed this evidence thoroughly before recommending tirzepatide in December 2024, you can read the full recommendation at NICE technology appraisal TA1026.

It's worth being clear about what tirzepatide products are not. Tirzepatide is not available as a tablet in the UK. There is no generic version. The only licensed UK product is Mounjaro, made by Eli Lilly, sourced through the licensed supply chain. If you see tirzepatide products advertised without a prescription from sellers you can't verify on the GPhC register, that's a serious red flag. The MHRA has raided illicit manufacturing sites producing counterfeit tirzepatide pens, and fake products have caused harm.

Who tirzepatide products are licensed for in the UK

Mounjaro carries two UK licences: one for weight management and one for type 2 diabetes. For weight management, the licensed criteria are adults with a BMI of 30 or above, or adults with a BMI of 27 or above who have at least one weight-related condition, such as high blood pressure, high cholesterol, obstructive sleep apnoea, prediabetes or type 2 diabetes. For some ethnic backgrounds, UK guidance applies thresholds that are 2.5 kg/m² lower than the standard figures.

A BMI that meets those numbers doesn't automatically mean tirzepatide is appropriate. A prescriber assesses the full picture: your health history, current medications, any conditions that would make tirzepatide unsuitable, and whether a clinical assessment has confirmed your identity and weight. Tirzepatide is not licensed for under-18s, and it's not recommended during pregnancy, while breastfeeding, or when actively trying to conceive.

People using oral contraceptives should be aware that tirzepatide may reduce pill absorption, particularly in the first four weeks of treatment and for four weeks after each dose increase. Adding a barrier method during those windows is the standard NHS advice. More on Mounjaro's licensed uses covers this in detail. If you're weighing up which product might suit your situation, the weight-loss treatment overview sets out the full picture of options.

Accessing tirzepatide products through a registered pharmacy

Tirzepatide is a Prescription-Only Medicine. The only legal route to obtaining it in the UK is a valid prescription issued following a genuine clinical assessment. That assessment can happen through the NHS (though eligibility criteria are strict and phased, and waiting times vary) or through a regulated private pharmacy like nume.

Through a private route, there are no waiting lists and no referral requirements. What there is, in every case, is a prescriber who reviews your consultation before any prescription is issued. At nume, that review is carried out by a GPhC-registered Independent Prescriber on the same day you submit. Photo ID and live weight verification are part of the process. If you're curious about the cost involved with private tirzepatide treatment, the Mounjaro online access page walks through what to look for and what legitimate pricing typically includes. The consultation page is the starting point if you'd like a prescriber to assess your suitability.

There are also products related to tirzepatide worth knowing about. Tirzepatide-adjacent and comparable medicines includes a factual rundown of how Mounjaro sits alongside other licensed options. And for background on who manufactures and authorises these products, Eli Lilly's role in producing Mounjaro is worth a read.